*Refers to median lead time to clinical progression. In the real-world literature, strong correlations between PFS and TTNT have been demonstrated.3
†Molecular response defined as a significant decrease in cDNA after starting therapy. 
1‡Elevated response defined as 298% decrease in cDNA after starting therapy.2

Important Note: Guardant Reveal was developed as Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.